'''Solanezumab''' (proposed [[International Nonproprietary Name|INN]], LY2062430<ref name=":0">{{Cite journal|title=Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease|journal=Alzheimer’s & Dementia|volume=8}}</ref>) is a [[monoclonal antibodies|monoclonal antibody]] being investigated by [[Eli Lilly and Company|Eli Lilly]] as a [[neuroprotection|neuroprotector]]<ref>[http://www.who.int/entity/medicines/publications/druginformation/innlists/PL100prepubli.pdf International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy)], ''World Health Organization''.</ref> for patients with [[Alzheimer's disease]].<ref>{{ClinicalTrialsGov|NCT00749216|Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease}}</ref><ref>{{ClinicalTrialsGov|NCT00905372|Effect of LY2062430 on the Progression of Alzheimer's Disease (EXPEDITION)}}</ref> The drug originally attracted extensive media coverage proclaiming it a breakthrough, but it has failed to show promise in Phase III trials.<ref>{{cite journal |vauthors=McCartney M |title=Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease |journal=BMJ |volume=351 |issue= |pages=h4064 |year=2015 |pmid=26208710 |doi=10.1136/bmj.h4064 |url=}}</ref>

 
== Adverse effects ==
